TG Therapeutics (STU:NKB2) Other Operating Expense : €-0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Other Operating Expense?

TG Therapeutics's Other Operating Expense for the three months ended in Mar. 2024 was €-0.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.0 Mil.

TG Therapeutics's quarterly Other Operating Expense increased from Sep. 2023 (€-0.0 Mil) to Dec. 2023 (€-0.0 Mil) but then declined from Dec. 2023 (€-0.0 Mil) to Mar. 2024 (€-0.0 Mil).

TG Therapeutics's annual Other Operating Expense stayed the same from Dec. 2021 (€-0.0 Mil) to Dec. 2022 (€-0.0 Mil) but then increased from Dec. 2022 (€-0.0 Mil) to Dec. 2023 (€0.0 Mil).

TG Therapeutics Other Operating Expense Historical Data

The historical data trend for TG Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Other Operating Expense Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

TG Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

TG Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.0 Mil.

TG Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (STU:NKB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

TGTX:USA NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines